Want to see ALVO full AI Analyst Report?
ALVO Stock Chart & Stats
$3.61
$0.06(0.46%)
At close: 4:00 PM EST
$3.61
$0.06(0.46%)
Day’s Range― - ―
52-Week Range$2.94 - $9.94
Previous CloseN/A
Volume41.59K
Average Volume (3M)903.67K
Market Cap
$1.35B
Enterprise Value$2.62B
Total Cash (Recent Filing)$63.83M
Total Debt (Recent Filing)$1.46B
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Aug 19, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding390,431,500
10 Day Avg. Volume500,649
30 Day Avg. Volume903,673
Financial Highlights & Ratios
PEG Ratio-0.46
Price to Book (P/B)-5.03
Price to Sales (P/S)2.44
P/FCF Ratio-12.49
Enterprise Value/Market Cap1.94
Enterprise Value/Revenue4.67
Enterprise Value/Gross Profit7.62
Enterprise Value/Ebitda50.46
Forecast
1Y Price Target
$4.00Price Target Upside10.80% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering1
EPS Forecast (FY)-0.01
Revenue Forecast (FY)$660.98M
Bulls Say, Bears Say
Bulls Say
Gross Margin StrengthSustained ~57–60% gross margins indicate the core biosimilars manufacturing and R&D model converts revenue to durable gross profit. High product-level margins provide structural buffer as sales scale, improving the odds of sustained profitability once throughput and approvals normalize.
Manufacturing DiversificationA Fujifilm technology-transfer and U.S. supply arrangement materially reduces single-site operational risk and supports U.S. launches. Durable benefit: diversified capacity shortens supply timelines, aids regulatory confidence, and underpins commercialization of multiple biosimilar launches.
Commercial Traction & PortfolioMarket-share gains for AVT02 and broad geographic presence reflect repeatable commercial execution and partner-led distribution. A growing approved product base and partner network support recurring product and supply revenues, reducing reliance on single approvals over the medium term.
Bears Say
Capital Structure StrainHeavy debt relative to assets and persistent negative equity materially constrain financial flexibility. Over the next several quarters this elevates refinancing risk and limits ability to fund capex or absorb delays, making growth contingent on successful financings or rapid cash generation.
Persistent Cash BurnOngoing negative OCF and FCF show the business is not yet self-funding. Reliance on external capital increases dilution and execution risk; until product margins and throughput recover, cash burn will pressure liquidity and force further financing or cutbacks.
Regulatory / Throughput OverhangRegulatory findings prompted deliberate production slowdowns and contributed to low product margins. Such inspection-driven capacity limits can persist through remediation and reinspection cycles, delaying U.S. approvals, compressing product margins, and creating durable uncertainty in near-term revenue ramps.
Alvotech News
ALVO FAQ
What was Alvotech’s price range in the past 12 months?
Alvotech lowest stock price was $2.94 and its highest was $9.94 in the past 12 months.
What is Alvotech’s market cap?
Alvotech’s market cap is $1.35B.
When is Alvotech’s upcoming earnings report date?
Alvotech’s upcoming earnings report date is Aug 19, 2026 which is in 29 days.
How were Alvotech’s earnings last quarter?
Alvotech released its earnings results on May 06, 2026. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.047 by -$0.043.
Is Alvotech overvalued?
According to Wall Street analysts Alvotech’s price is currently Undervalued.
Does Alvotech pay dividends?
Alvotech does not currently pay dividends.
What is Alvotech’s EPS estimate?
Alvotech’s EPS estimate is -0.04.
How many shares outstanding does Alvotech have?
Alvotech has 390,431,500 shares outstanding.
What happened to Alvotech’s price movement after its last earnings report?
Alvotech reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.047. Following the earnings report the stock price went down -10.364%.
Which hedge fund is a major shareholder of Alvotech?
Currently, no hedge funds are holding shares in ALVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alvotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$4.00 (10.80% Upside)
$4.00 (10.80% Upside)
Blogger Sentiment
Bullish
ALVO Sentiment 70%
Sector Average 66%
Sector Average 66%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.48%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
14.11%
Trailing 12-Months
Company Description
Alvotech
Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of inflammatory illnesses, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Similarly, AVT04 is a biosimilar version of Stelara, targeting inflammatory conditions such as psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. For ophthalmic conditions, AVT06 serves as a biosimilar to Eylea, intended for the treatment of age-related macular degeneration, macular edema, and diabetic retinopathy. Currently in preclinical stages, AVT03 is a biosimilar to Xgeva and Prolia, with the goal of preventing bone fractures, alleviating spinal cord compression, reducing the necessity for radiation or bone surgery in certain cancer patients, and both preventing bone loss and increasing bone density. Additionally, Alvotech's pipeline features AVT05, an early-stage biosimilar for Simponi and Simponi Aria, which is being developed for various inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Other promising candidates include AVT16, an immunology biosimilar; AVT23, a late-stage biosimilar to Xolair, aimed at treating nasal polyps; and AVT33, an oncology biosimilar. Established in 2013, Alvotech maintains its primary corporate headquarters in Reykjavik, Iceland.
ALVO Stock 12 Month Forecast
Average Price Target
$4.00
▲(10.80% Upside)
Technical Analysis
Perrigo Company
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
HUTCHMED
―
Amneal Pharmaceuticals
―
Ownership Overview
―
Insiders
1.22% Mutual Funds
0.04% Other Institutional Investors
98.26% Public Companies and
Individual Investors